Life Science

Small ubiquitin-related modifier (SUMO) proteins are conjugated to numerous intracellular targets and serve to modulate protein interaction, localization, activity, and stability. SUMO (also known as &#39Smt3&#39 and &#39sentrin&#39 in other

A selective, irreversible inhibitor of BTK (IC₅₀ = 0.5 nM in vitro in B cell lymphoma cell lines) that targets and covalently binds to BTK at cysteine-481 inhibits osteoclast function and reduces osteoclast-stimulated proliferation of

A selective, irreversible inhibitor of BTK (IC₅₀ = 0.5 nM in vitro in B cell lymphoma cell lines) that targets and covalently binds to BTK at cysteine-481 inhibits osteoclast function and reduces osteoclast-stimulated proliferation of

A selective, irreversible inhibitor of BTK (IC₅₀ = 0.5 nM in vitro in B cell lymphoma cell lines) that targets and covalently binds to BTK at cysteine-481 inhibits osteoclast function and reduces osteoclast-stimulated proliferation of

A selective, irreversible inhibitor of BTK (IC₅₀ = 0.5 nM in vitro in B cell lymphoma cell lines) that targets and covalently binds to BTK at cysteine-481 inhibits osteoclast function and reduces osteoclast-stimulated proliferation of

A partial agonist of the GABAA receptor that acts at the benzodiazepine binding site, dose-dependently stimulating GABA currents with a threshold of 0.3-1.

A partial agonist of the GABAA receptor that acts at the benzodiazepine binding site, dose-dependently stimulating GABA currents with a threshold of 0.3-1.

A partial agonist of the GABAA receptor that acts at the benzodiazepine binding site, dose-dependently stimulating GABA currents with a threshold of 0.3-1.

A partial agonist of the GABAA receptor that acts at the benzodiazepine binding site, dose-dependently stimulating GABA currents with a threshold of 0.3-1.

A potent group IVA cPLA2 inhibitor (XI(50) = 0.022) reduces thermal hyperalgesia evoked by carrageenan injection of rat hind paw (ED₅₀ = 1.2 mg/kg) does not inhibit COX activity or interfere with CB1 receptor signaling.

A potent group IVA cPLA2 inhibitor (XI(50) = 0.022) reduces thermal hyperalgesia evoked by carrageenan injection of rat hind paw (ED₅₀ = 1.2 mg/kg) does not inhibit COX activity or interfere with CB1 receptor signaling.

A potent group IVA cPLA2 inhibitor (XI(50) = 0.022) reduces thermal hyperalgesia evoked by carrageenan injection of rat hind paw (ED₅₀ = 1.2 mg/kg) does not inhibit COX activity or interfere with CB1 receptor signaling.